keyword
MENU ▼
Read by QxMD icon Read
search

Ixekizumab

keyword
https://www.readbyqxmd.com/read/29144382/treatment-approaches-to-moderate-to-severe-psoriasis
#1
REVIEW
Paolo Gisondi, Micol Del Giglio, Giampiero Girolomoni
Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this review, the factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab, secukinumab, ixekizumab, and ustekinumab are discussed...
November 16, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29143230/the-efficacy-of-biologic-therapy-for-the-management-of-palmoplantar-psoriasis-and-palmoplantar-pustulosis-a-systematic-review
#2
REVIEW
Isabelle M Sanchez, Eric Sorenson, Ethan Levin, Wilson Liao
INTRODUCTION: Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP...
November 15, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29131037/paradoxical-reactions-anti-tumor-necrosis-factor-alpha-agents-ustekinumab-secukinumab-ixekizumab-and-others
#3
Lluís Puig
Paradoxical reactions during treatment with a biologic agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition, which usually remains under control (even though there may be a change in morphology or phenotype). Paradoxical reactions were initially described as isolated case reports or case series in patients treated with anti-tumor necrosis factor (TNF) α agents, first in inflammatory rheumatic diseases, later in psoriasis and inflammatory bowel disease...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29116597/response-to-tetanus-and-pneumococcal-vaccination-following-administration-of-ixekizumab-in-healthy-participants
#4
Elisa V Gomez, Jessie L Bishop, Kimberley Jackson, Talia M Muram, Diane Phillips
BACKGROUND: Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis. OBJECTIVE: The objective of this study was to determine if the immune response to tetanus and pneumococcal vaccines in healthy subjects administered IXE was noninferior to control. METHODS: In a randomized, open-label, parallel-group study, adult subjects received vaccinations alone (N = 42, control) or in combination with 160 mg IXE subcutaneously 2 weeks prior to vaccination and 80 mg IXE on the day of vaccination (N = 41, IXE)...
November 7, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29090075/lentiginous-eruption-in-resolving-psoriasis-plaques-during-treatment-with-ixekizumab-a-case-report-and-review-of-the-literature
#5
Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen
No abstract text is available yet for this article.
October 11, 2017: Dermatology Reports
https://www.readbyqxmd.com/read/29058501/review-of-il-17-inhibitors-for-psoriasis
#6
Mina Amin, Kavita Darji, Daniel J No, Tina Bhutani, Jashin J Wu
BACKGROUND: The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasis patients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. OBJECTIVE: The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data. METHODS: We reviewed the results of phase III clinical trials for the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab...
October 23, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29036249/cost-effectiveness-analysis-of-ixekizumab-vs-etanercept-and-their-manufacturer-recommended-dosing-regimens-in-moderate-to-severe-plaque-psoriasis
#7
Jeremy Udkoff, Lawrence F Eichenfield
INTRODUCTION: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Food and Drug Administration (FDA) approved ixekizumab for treating psoriasis. Evaluating the cost-effectiveness of these therapies is crucial for medical decision making and our objective was to determine the cost-effectiveness of various ixekizumab dosing frequencies compared with etanercept...
October 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28991370/ixekizumab-treatment-for-psoriasis-integrated-efficacy-analysis-of-three-double-blinded-controlled-studies-uncover-1-uncover-2-uncover-3
#8
K A Papp, C L Leonardi, A Blauvelt, K Reich, N J Korman, M Ohtsuki, C Paul, S Ball, G S Cameron, J Erickson, L Zhang, L Mallbris, C E M Griffiths
BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. OBJECTIVES: This analysis represents an overview of the efficacy outcomes from three Phase 3 psoriasis studies. METHODS: Data were integrated from the 12-week induction period of three studies in which patients received ixekizumab 80 mg every 2 (IXE Q2W; N=1169) or 4 weeks (IXE Q4W; N=1165) after an initial 160-mg dose for both, etanercept (ETN) (50 mg biweekly; N=740; two studies), or placebo (PBO) (N=792)...
October 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28951376/-a-systematic-review-of-anti-interleukin-17-antibody-in-the-treatment-of-plaque-psoriasis
#9
Xiao-Dong Fan, Xiang Xia, Chun-Yan Zhang, Wen-Qiang Kong, Chun-Yang Zhou, Biao DU
OBJECTIVE: To evaluate the efficacy and safety of anti-interleukin-17 antibody in the treatment of plaque psoriasis. METHDOS: Randomized controlled trials (RCT) of anti-interleukin-17 antibody (Secukinumab, Brodalumab, and Ixekizumab) in the treatment of plaque psoriasis published between January, 2000 and March, 2017 were searched from PubMed, Cochrane Library, EBSCO, EMbase, CBM, CNKI, VIPdetabase, and Wangfang database. The quality of the retrieved trials was evaluated and the results of studies were analyzed using RevMan 5...
September 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28929168/long-term-impact-of-ixekizumab-on-psoriasis-itch-severity-results-from-a-phase-iii-clinical-trial-and-long-term-extension
#10
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, Gil Yosipovitch
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance therapy (80-mg ixekizumab every 4 weeks [IXEQ4W]) on itch severity, using the Itch Numeric Rating Scale, in psoriasis patients who received ixekizumab, placebo, or etanercept for 12 weeks in the Phase III UNCOVER-3 trial...
September 20, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28926467/a-systematic-review-and-meta-analysis-of-efficacy-and-safety-of-novel-interleukin-inhibitors-in-the-management-of-psoriatic-arthritis
#11
Jawad Bilal, Irbaz Bin Riaz, Muhammad Umar Kamal, Mazen Elyan, Dominick Sudano, Muhammad Asim Khan
OBJECTIVE: The aim of this study was to systemically review the efficacy and safety of inhibitors of interleukin 6 (IL-6): clazakizumab, IL-12/23: ustekinumab, and IL-17A: secukinumab, brodalumab, and ixekizumab in psoriatic arthritis (PsA). METHODS: The literature search was conducted using MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science. We included randomized controlled trials that assessed the efficacy of IL inhibitors and reported American College of Rheumatology 20 response at 24 weeks...
September 19, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#12
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28917383/efficacy-and-safety-of-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-results-through-108%C3%A2-weeks-of-a-randomized-controlled-phase-3-clinical-trial-uncover-3
#13
RANDOMIZED CONTROLLED TRIAL
Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah O Agada, Kristian Reich
BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. OBJECTIVE: To evaluate the efficacy and safety of ixekizumab through 108 weeks of treatment in UNCOVER-3. METHODS: Patients (N = 1346) were randomized 2:2:2:1 to 80 mg ixekizumab every 2 or 4 weeks, 50 mg etanercept twice weekly, or placebo. At week 12, patients switched to ixekizumab every 4 weeks during a long-term extension (LTE) period...
November 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28903122/impact-of-ixekizumab-treatment-on-depressive-symptoms-and-systemic-inflammation-in-patients-with-moderate-to-severe-psoriasis-an-integrated-analysis-of-three-phase-3-clinical-studies
#14
Christopher E M Griffiths, Maurizio Fava, Andrew H Miller, James Russell, Susan G Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
BACKGROUND: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe. METHODS: Data were integrated from 3 randomized, double-blind, controlled phase 3 trials. At baseline and week 12, depressive symptoms and inflammation were assessed by the 16-item Quick Inventory of Depressive Symptomology - Self-Report (QIDS-SR16) and by a high-sensitivity assay of serum C-reactive protein (hsCRP), respectively...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28895664/severe-and-acute-complications-of-biologics-in-psoriasis
#15
Elias Oussedik, Nupur U Patel, Devin R Cash, Angela S Gupta, Steven R Feldman
Biologic therapies have revolutionized the approach to immune-mediated diseases such as psoriasis. Due to their favorable safety profiles and excellent efficacy, biologic agents are considered the gold standard for moderate-to-severe psoriasis. The aim of this paper is to saliently review the severe and acute complications of the Food and Drug Administration (FDA) approved biologic agents for psoriasis. Reviewed agents include tumor necrosis factor alpha inhibitors (etanercept, infliximab, and adalimumab), interleukin 12/23 inhibitors (ustekinumab), and interleukin 17 (IL-17) inhibitors (secukinumab and ixekizumab)...
December 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28894754/natural-modulators-of-endosomal-toll-like-receptor-mediated-psoriatic-skin-inflammation
#16
REVIEW
Chao-Yang Lai, Yu-Wen Su, Kuo-I Lin, Li-Chung Hsu, Tsung-Hsien Chuang
Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. Therefore, inhibitors of endosomal TLR activation are being investigated for their ability to treat this disease. The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28887948/psoriasis-pathogenesis-and-the-development-of-novel-targeted-immune-therapies
#17
REVIEW
Jason E Hawkes, Tom C Chan, James G Krueger
Psoriasis is caused by a complex interplay between the immune system, psoriasis-associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease primarily driven by pathogenic T cells that produce high levels of IL-17 in response to IL-23. The discovery of the central role for the IL-23/type 17 T-cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition...
September 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28881462/impact-of-ixekizumab-on-facial-psoriasis-and-related-quality-of-life-measures-in-moderate-to-severe-psoriasis-patients-12-week-results-from-2-phase-iii-trials
#18
C Paul, L Guenther, H Torii, H Sofen, R Burge, C Y Lin, A Potts Bleakman, L Mallbris, Y Poulin
BACKGROUND: Facial psoriasis was reported in 17-68% of patients with psoriasis and shown to have a negative impact on patients' personal and health-related quality of life (HRQoL). OBJECTIVES: Explore the association of facial psoriasis with patients' HRQoL and assess the relationship between ixekizumab (IXE) and improvement in facial psoriasis and changes in HRQoL. METHODS: This work reports the combined results of 2 phase III multicenter, randomized, double-blind, placebo-controlled, active-comparator trials in patients with moderate-to-severe psoriasis...
September 7, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28825875/monoclonal-antibodies-inhibiting-il-12-23-and-17-for-the-treatment-of-psoriasis
#19
Caleb Jeon, Sahil Sekhon, Di Yan, Ladan Afifi, Mio Nakamura, Tina Bhutani
Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of the adult US population, characterized by well-demarcated, erythematous plaques with silver scale. Psoriasis is associated with many comorbidities including cardiometabolic disease and can have a negative impact on quality of life. The current armamentarium of psoriasis treatment includes topical therapies, phototherapy, oral immunosuppressive therapies, and biologic agents. Over the past 2 decades, there has been rapid development of novel biologic therapies for the treatment of moderate-to-severe plaque psoriasis...
October 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28792259/improvements-in-psoriasis-within-different-body-regions-vary-over-time-following-treatment-with-ixekizumab
#20
Andrew Blauvelt, Talia M Muram, Kyoungah See, Craig H Mallinckrodt, Jeffrey J Crowley, Peter van de Kerkhof
BACKGROUND: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. OBJECTIVE: Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. METHODS: Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, N = 792; UNCOVER-2, -3, N = 361), 50 mg ETN twice weekly (N = 740), or 80 mg ixekizumab every 2 (IXE Q2W; N = 1169; N = 736) or 4 weeks (IXE Q4W; N = 1165; N = 733) after a 160-mg starting dose...
August 9, 2017: Journal of Dermatological Treatment
keyword
keyword
64229
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"